Elekta, Xoft ink sales development agreement
Xoft, a developer of the Axxent Electronic Brachytherapy system, and Elekta, a provider of radiation oncology and non-invasive neurosurgery, have signed a sales development agreement.
Under the agreement, Elekta will share identified sales opportunities for the Xoft Axxent Electronic Brachytherapy in the radiation oncology market, according to the Fremont, Calif.-based Xoft. The non-exclusive agreement allows Elekta to expand its revenue to include procedures performed outside shielded rooms by partially sharing in revenues Xoft receives from the sale of the Electronic Brachytherapy controller, the company said.
The companies will also explore other areas of collaboration, which could include international sales and joint development agreements, Xoft said.
Xoft said its Axxent is cleared by the FDA for the treatment of early stage breast cancer, and is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.
Under the agreement, Elekta will share identified sales opportunities for the Xoft Axxent Electronic Brachytherapy in the radiation oncology market, according to the Fremont, Calif.-based Xoft. The non-exclusive agreement allows Elekta to expand its revenue to include procedures performed outside shielded rooms by partially sharing in revenues Xoft receives from the sale of the Electronic Brachytherapy controller, the company said.
The companies will also explore other areas of collaboration, which could include international sales and joint development agreements, Xoft said.
Xoft said its Axxent is cleared by the FDA for the treatment of early stage breast cancer, and is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.